Sugi Predict

Sugi Predict / Compounds / SCHEMBL2118476

SCHEMBL2118476

SCHEMBL2118476

Cc1nc2ccccc2c(=O)n1-c1ccc(O)cc1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.76
▸ HSD17B10 Q99714 1/20 0.72
▸ POLB P06746 3/20 0.69
▸ ALDH1A1 P00352 3/20 0.68
▸ ALOX12 P18054 1/20 0.63
▸ TP53 P04637 1/20 0.63
▸ LMNA P02545 2/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ GRM1 Q13255 1/20 0.61
▸ MEN1 O00255 1/20 0.60
▸ KLK7 P49862 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ ESR1 P03372 1/20 0.59
▸ ESR2 Q92731 1/20 0.59
▸ GFER P55789 1/20 0.59
▸ HRH3 Q9Y5N1 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30122631 0.90 MAPK1 (0.75) MAPK1HSD17B10POLBALDH1A1ALOX12
SCHEMBL1682746 0.90 MAPK1 (0.75) MAPK1HSD17B10POLBALDH1A1ALOX12
SCHEMBL2631381 0.89 MAPK1 (0.74) MAPK1HSD17B10POLBALDH1A1ALOX12
SCHEMBL4391482 0.86 MAPK1 (0.70) MAPK1HSD17B10POLBALDH1A1ALOX12
SCHEMBL9336504 0.86 MAPK1 (0.70) MAPK1HSD17B10POLBALDH1A1ALOX12
SCHEMBL4958753 0.86 MAPK1 (0.70) MAPK1HSD17B10POLBALDH1A1ALOX12
SCHEMBL30726093 0.86 MAPK1 (0.70) MAPK1HSD17B10POLBALDH1A1ALOX12
SCHEMBL29103865 0.86 MAPK1 (0.70) MAPK1HSD17B10POLBALDH1A1ALOX12
SCHEMBL29154649 0.84 ALDH1A1 (0.76) MAPK1POLBALDH1A1LMNAMEN1
SCHEMBL15014070 0.84 MAPK1 (0.67) MAPK1HSD17B10POLBALDH1A1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 — — EP disclosed
US-8691811-B2 Quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-04-08 — — US disclosed
EP-2350085-B1 QUINAZOLINONE LINKED PYRROLO[2,1 -C][1.4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2013-06-19 — — EP disclosed
EP-2350085-B1 QUINAZOLINONE LINKED PYRROLO[2,1 -C][1.4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2013-06-19 — — EP disclosed
US-8268842-B2 Fused ring 4-oxopyrimidine derivative MSD K.K. (JP) 2012-09-18 — — US disclosed
US-20120095214-A1 QUINAZOLINONE LINKED PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-04-19 — — US disclosed
US-20120095214-A1 QUINAZOLINONE LINKED PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-04-19 — — US disclosed
EP-2350085-A1 QUINAZOLINONE LINKED PYRROLOÝ2,1 -C¨Ý1.4¨BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF Council Of Scientific & Industrial Research (IN) 2011-08-03 — — EP disclosed
CN-1918128-B fused ring 4-oxo-pyrimidine derivatives BANYU PHARMA CO LTD 2011-01-26 — — CN disclosed
WO-2010058416-A1 QUINAZOLINONE LINKED PYRROLO[2,1 -C][1.4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-05-27 — — WO disclosed
WO-2010058416-A1 QUINAZOLINONE LINKED PYRROLO[2,1 -C][1.4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-05-27 — — WO disclosed
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-08-20 — — US disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 — — US disclosed
CN-1918128-A Fused ring 4-oxo-pyrimidine derivatives BANYU PHARMA CO LTD (JP) 2007-02-21 — — CN disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 — — EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 MAPK1 2026/4885HSD17B10 2223/4885POLB 3042/4885
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 MAPK1 2026/4885HSD17B10 2223/4885POLB 3042/4885
US-20120095214-A1 QUINAZOLINONE LINKED PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF GABRA1, CYP2C19, GABRA5 MAPK1 2552/4885HSD17B10 1361/4885POLB 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.